Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph 1, BXQ-350 as a Single Agent by IV w/ Advanced Solid Tumors and Recurrent High-Grade Gliomas

Protocol: OSU-16182

Full Title

Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients with Advanced Solid Tumors and Recurrent High-Grade Gliomas

Brain Cancer Genitourinary Cancers Endocrine Cancers Gastrointestinal Cancers Gynecologic Cancers Bone Cancer Head & Neck Cancers Skin Cancers Sarcoma Vulvar Cancer Anal Cancer Pituitary Tumor Liver Cancer Merkel Cell Carcinoma Cervical Cancer Squamous Cell Carcinoma Neuroendocrine Cancer Stomach (Gastric) Cancer Endometrial Cancer Testicular Cancer Esophageal Cancer Bone & Spine Sarcoma Soft Tissue Sarcoma Laryngeal Cancer Skull Base Colon Cancer Small Intestine Cancer Oropharyngeal Cancer Bladder Cancer Parathyroid Cancer Kidney Cancer Ocular Melanoma Gastrointestinal Carcinoid Tumors Breast Cancer Vaginal Cancer Lip & Oral Cavity Cancer Rectal Cancer Gliomas Basal Cell Carcinoma Melanoma Other Brain Cancers Prostate Cancer Kaposi Sarcoma Spine Tumors Lung Cancers